David B. Clifford, MD Washington University in St. Louis. Disclaimers
|
|
- Sharyl Henry
- 6 years ago
- Views:
Transcription
1 HIV Associated Neurocognitive Disorders (HAND) David B. Clifford, MD Washington University in St. Louis Disclaimers Funding: NIH: NIAID, NINDS, NIMH, NIA, Fogarty Consulting: Biogen, Cytheris, Genzyme, Pfizer, Genentech, Jannsen, Millennium, Novartis, BMS, Roche Clinical study support: Biogen, Glaxo, Pfizer, BMS, Neurogesx, Genentech 1
2 HIV 1 Associated Neurologic Problems Primary HIV associated conditions HIV associated neurocognitive disorder and dementia Myelopathy Peripheral neuropathy Myopathy HIV Associated Dementia (HAD) Slide 4 Decreased concentration Motor slowing Behavioral changes 2
3 Slide 5 HIV-Associated Dementia (HAD) Formerly AIDS Dementia Complex Occurs with low CD4 Progressive untreated death in 6 months Correlates at least moderately to active viral replication (in CNS) CSF VL high Correlates to immune activation markers Pathology: Multinucleated giant cells Slide 6 Approved Antiretroviral Agents DDC 3TC 3TC/ZDV DLV ABC TDF 3TC/ABC FTC/TDF ETR ZDV DDI d4t NVP EFV ABC/3TC/ZDV TDF/FTC/EFV SQV NFV LPV/r T-20 TPV SQV.sgc APV ATV DRV Nucleoside RTI Non-Nucleoside RTI Protease Inhibitor Fusion Inhibitor CCR Inhibitor Integrase Inhibitor RTV IDV RFV MVC RTG 3
4 Slide 7 Slide 8 Successful HIV Therapy Helps ( A Lot) Probable dementia Toxoplasmosis Progressive multifocal leukoencephalopathy Probable or possible dementia Cryptococcal meningitis CNS lymphoma Incidence rates er 1,000 person-years) (pe Multicenter AIDS Cohort Calendar Year HAART Sacktor, personal comm 200 4
5 Neurocognitive Impairment in the Pre-ARV, Pre-HAART and HAART Eras 100% Grant 1987 HNRC CHARTER 2008 Slide 9 Per rcent Impaired 75% 50% 25% 0% HIV- CDC-A CDC-B CDC-C Frascati Classification of HIV Associated Neurocognitive Disorders (HAND) ANI = Asymptomatic neurocognitive impairment MND = Mild neurocognitive disorder HAD = HIV 1 associated dementia 5
6 HIV Associated Neurocognitive Disorders (HAND): Frascati Criteria HIV-associated Dementia marked cognitive impairment with marked functional impairment Mild Neurocognitive Disorder cognitive impairment with mild functional impairment Asymptomatic Neuropsychological Impairment abnormality in two or more cognitive abilities Antinori, et al., Neurology 2007 CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO HIV Associated Neurocognitive Disorders (HAND): Frascati Criteria HIV-associated Dementia marked cognitive impairment with marked functional impairment Mild Neurocognitive Disorder cognitive impairment with mild functional impairment Asymptomatic Neuropsychological Impairment abnormality in two or more cognitive abilities Antinori, et al., Neurology 2007 CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 6
7 Asymptomatic HIV-associated Neurocognitive Disorder (ANI) Increases Risk for Future Symptomatic Decline: A CHARTER Longitudinal Study Robert Heaton, PhD 1, Donald Franklin, BS 1, Steven Woods, PsyD 1, Christina Marra, MD 2, David Clifford, MD 3, Benjamin Gelman, MD,PhD 4, Justin McArthur, MBBS 5, Susan Morgello, MD 6, Allen McCutchan, MD 1, and Igor Grant, MD 1 for the CHARTER Group 1 University of California, San Diego; 2 University of Washington, Seattle; 3 Washington University, St. Louis; 4 University of Texas Medical Branch, Galveston; 5 Johns Hopkins University, 6 Mount Sinai School of Medicine CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO Diagnosis CHARTER Neurocognitive Test Battery Verbal Fluency» Letter Fluency» Category Fluency Speed of Information Proc.» WAIS-III Symbol Search» WAIS-III Digit Symbol» Trail Making Test Part A Attention/Working Memory» Paced Auditory Serial Addition Test - 50» WAIS-III Letter-Number Sequencing Motor» Grooved Pegboard Abstraction/Executive» Wisconsin Card Sorting Test 64» Trail Making Test Part B Learning and Memory» Hopkins Verbal Learning Test-R» Brief Visuospatial Memory Test-R» Story Memory Test» Figure Memory Test Everyday Functioning: Patient s Assessment of Own Functioning Inventory Activities of Daily Living Scale CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 7
8 Participants 347 longitudinal CHARTER participants with up to 90 months of follow-up (median 45.2 months)» 226 NML cases: No neurocognitve impairment and no selfreported or observed declines in everyday functioning» 121 ANI cases: Neurocognitvely impaired, but no self-reported or observed declines in everyday functioning Participants completed neuromedical, laboratory, neurocognitive, and both self-report and performancebased measures of everyday functioning approximately every 6 months CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO Self-Report Functional Impairment Measures Patients Assessment of Own Functioning Inventory (PAOFI): Measures cognitive complaints over 5 domains (eg., memory, language, cognition)» Symptomatic = 3 or more complaints Activities of Daily Living (ADL): Measures increased dependence in completing basic activities of daily living (eg., housekeeping, cooking, managing g finances)» Symptomatic = declines in 2 or more areas at least partially attributed to cognitive problems Self-report symptomatic HAND requires both PAOFI and ADL to be symptomatic CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 8
9 Performance-based Functional Impairment Measures Medication Management Test-Revised (MMT-R): Assesses ability to perform tasks related to medication management» Tasks include ability to correctly place pills in a pill organizer according to prescription schedule and ability to infer answers from prescription labels» Symptomatic = Score 1SD below the mean of cognitively normal sample Valpar System 3000 Work Samples and Computerized Assessment: Assesses abilities considered important for performing work-related tasks» Symptomatic = Score 1SD below the mean of cognitively normal sample CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO Baseline Comparison of ANI and NML: Background Characteristics NML (n=226) ANI (n=121) P-value Age 43.0 (8.6) 44.8 (8.0) Education 12.9 (2.4) 13.5 (2.2).04 % Male 81.9% 81.8% % Caucasian 45.6% 46.3% % Lifetime Substance Dx 71.2% 69.4% % with Comorbidity 22.6% 44.6% <.0001 CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 9
10 Baseline Comparison of ANI and NML: Disease Characteristics NML (n=226) ANI (n=121) P-value % AIDS 56.2% 62.8% Current CD4 459 [ ] 425 [ ] Nadir CD4 201 [61-370] 162 [38-273].03 % on ART 66.2% 72.7% Est. Duration HIV+ (months) (75.0) (81.6) % HCV+ 20.4% 27.3 CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO ANI Increases Risk for Symptomatic HAND: Based on Self-Report of Functional Impairment NML: n=226 ANI: n=121 (Asymptomatic) Surviving ( p=.003 Relative Risk: 2.30 CI: 1.38, 3.86 CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 10
11 ANI Increases Risk for Symptomatic HAND: Performance-based Functional Impairment NML: n=226 ANI: n=121 Surviving (Asymptomatic) p<.0001 Relative Risk: 4.70 CI: 2.93, 7.71 CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO ANI Increases Risk for Symptomatic HAND: Self-report or Performance-based NML: n=226 ANI: n=121 Surviving (Asymptomatic) p<.0001 Relative Risk: 3.02 CI: 2.08, 4.42 CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 11
12 Asymptomatic Neurologic Impairment May Predict Functional Decline Mechanism remains uncertain Cannot write off this substantial portion of successfully treated HIV patients Tracking change in this population is challenging Measures of cognitive function that can be repeated and tracked might be of value CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO International HIV Dementia Scale International HIV Dementia Scale Naming four objects Fingertapping Luria psychomotor learning task Recall of names Sacktor et al. Neurology ;1:A CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 12
13 CogState Executive Function ures/12_minute%20brochure%20rev 6_LowRes.pdf CROI 2010, Winston, et al CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO Diagnosis NPZ -4 used in ACTG Trail making A and B Symbol digit test Hopkins Verbal Learning test Robertson, et al, ALLRT CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO 13
14 Cognitive Screening Montreal Cognitive Assessment (MoCA) Broad balanced test Online and free Bedside scoring Being assessed in comparison with tools currently used that require licenses, and norming CNS HIV NEUROBEHAVIORAL HIV ANTI-RETROVIRAL THERAPY RESEARCH EFFECTS PROGRAM RESEARCH UNIVERSITY OF OF CALIFORNIA, SAN SAN DIEGO Cognitive Dysfunction in HIV AIDS Dementia (now HAD) Pre HAART HAND (ANI/MND) Post HAART 14
15 Slide 29 To develop effective treatment we need to know causes HAND now Evidence for direct viral mechanism poor Cytokines that formerly were most closely associated no longer provide reliable signal by the way, I m from Missouri where famously you have to Show me. Noninfectious pathologies and minimal changes correlated with HIV associated neurocognitive disorder, suggesting a shift in pathogenesis from florid HIV replication to other, diverse mechanisms 88% of sample had HAND 17.5 % has parenchymal HIV brain pathology which was associated to nadir CD4 and plasma viral load 15
16 Slide 31 To develop effective treatment we need to know causes HAND now? Co-morbidities Virus Inflammation Drugs Perfusion/Vascular Is this all due to non-hivassociated co-morbidities? Slide 32 Contribution of other factors to cognitive performance?trauma?drugs?hepatitis?cmv?psychiatric dx/rx 16
17 Neurocognitive Impairment by Co-Morbidity Status Slide 33 impairment % Total Minimal Moderate Severe Slide 34 Co-morbidity Large effect of co-morbid associated impairment masks HIV associated findings Only in the clean group can one see impact of HIV viral load, CD4 nadir Co-morbidity may set up environment for ongoing pathologic interaction with HIV and/or its consequences like inflammation 17
18 Slide 35 To develop effective treatment we need to know causes HAND now? Co-morbidities Virus Inflammation Drugs Perfusion/Vascular Viral Escape Slide 36 CNS is functional compartment Viral isolates may be unique Cells infected in CNS are monocytes/macrophag es with unique viral requirements Rx may differ Untreated HIV CSF generally one log lower VL than periphery During HAD CSF VL rises with autonomous CNS isolates Most often when peripheral virus controlled so is CSF 18
19 Peluso, Spudich et al, Poster 489 Symptomatic Viral Escape Slide 37 Controlled plasma viral load Subacute onset of new neurologic symptoms CSF demonstrated independent replication Drug selection based on virus in CSF improved clinical condition Implications of Viral Escape HIV therapy is not perfect Viral replication sometimes occurs in CNS and generates important resistance mutations Attention to virus in CNS remains critical Justify CSF analysis when new neurologic problems occur in HIV patient, even with good control in plasma Rarity suggest it doesn t explain common HAND 19
20 Slide 39 Does viral subtype matter? Work in Uganda with dementia suggests difference in risk between Subtype A and D Work in Ethiopia suggests Subtype C might have less neurovirulence Projects in Cape Town and in Brazil are addressing potential differences, to date seems less likely to be important HIV infection in the brain may not be fully reflected in blood studies and therapies not as effective in brain. 20
21 Slide 41 CNS Penetration-Effectiveness Ranks NRTIs Zidovudine Abacavir Lamivudine Didanosine Emtricitabine Stavudine Tenofovir Zalcitabine NNRTIs Nevirapine Delavirdine Etravirine Efavirenz PIs Indinavir-r Darunavir-r Atazanavir Nelfinavir Fosamprenavirr Atazanavir-r Ritonavir Indinavir Fosamprenavir Saquinavir Lopinavir-r Saquinavir-r Tipranavir-r Entry Inhs Vicriviroc Maraviroc Enfuvirtide Integrase Inhs Raltegravir CNS Penetration-Effectiveness Ranks Slide 42 Letendre S, et al. Arch Neurol 2008; 65:65-70 CPE 2010 Ranks Cross-Sectional Analysis 21
22 Slide 43 CNS Penetration Effectiveness Unproven CIT2 a randomized trial of rx based on CPE has been stopped Lack of proof by underpowered study doesn t completely discredit this idea More potent delivery of drugs contemplated, eg nanoparticles Drug entry might be double edged sword Toxicity of drugs is an increasing concern Slide 44 Damaged brain may heal poorly CD4 Nadir Legacy of prior damage Nadir CD4 count CHARTER analysis suggest significant impact of nadir <350 Data too limited to test higher h nadirs Treating a scar? Tough target Implies earlier rx could be helpful CROI 2010, Poster 429, Ellis, et al 22
23 Reduced Risk of NCI in those with Absent History of Severe Immunosuppression and Good Virologic Control 0.7 Nadir CD4 > 200/ Detectable VL 0.6 Nadir CD4 < 200/ Detectable VL lity of Impairment Nadir CD4 < 200/ Undetectable VL Probabi Nadir CD4 > 200/ Undetectable VL Changes in Brain Cortex: Damage to the computer Vacuolar Changes Synaptophysin 23
24 Slide 47 To develop effective treatment we need to know causes HAND now Co-morbidities Virus Inflammation Drugs Perfusion/Vascular Inflammation Ongoing Chronic Inflammation Biology of HIV includes chronic immune activation Microbial translocation/lps associated with dementia Slide 48 Brenchley et al, Nature Med,
25 ~60% still have elevated neopterin and IgG Index after 4 yrs HIV rx Slide 50 CSF Viral Escape Can Drive Ongoing CNS Immune Activation 25
26 Detection of microglial cell activation in patients on suppressive ART Garvey et al, CROI2012 Garvey L et al. CROI #78LB Accrual of inflammation in brain attenuated with ART in early infection CROI 2012 Young et al. Abstract #79 26
27 CMV Might Drive Inflammation and Neurocognitive Change CMV powerful antigenic stim that may reactivate and drive chronic inflammation Increases with aging and severity of nadir CD4 In 138 CHARTER patients serum CMV IgG correlated with neurocognitive impairment Fits model of co morbidity driving impairment Letendre, et al, Abstract 466, CROI 2012 Adjunctive Studies for HAND CPI 1189 (TNF alpha antagonist) Lexipafant (Platelet activating factor antagonist) Memantine (NMDA antagonist) Minocycline (Anti inflammatory and p38 MAP kinase inhibitor) Nimodipine (Calcium channel antagonist) Nitroglycerin (Vasodilator) OPC (antioxidant) Pentoxifylline (Platelet activating factor antagonist, TNAa antagonist) Peptide T (possible chemokine receptor blocker) Prednisone (Macrophagesuppression) Selegiline (deprenyl) (Monoamine oxidase B inhibitor) Thioctic acid (antioxidant) Valproic acid unknown Lithium GSK 3βinhibtion Cochrane Review,
28 Minocycline for HAND SIV model data Potential mechanisms Anti inflammatory/ neuroprotective via suppression of p38 MAP kinase Anti oxidant via inos inhibition Anti apoptotic Inhibits matrix metalloproteinases that may damage BBB?Anti viral effect in SIV A5235 is open placebo controlled dti trial of minocycline for HIV patients with cognitive impairment 28
29 A5235: Minocycline vs Placebo x 24 wks Pre-post NPZ8 Plot for A Week NPZ Minocycline Placebo Baseline NPZ8 Slide 58 To develop effective treatment we need to know causes HAND now? Co-morbidities Virus Inflammation Drugs Perfusion/Vascular 29
30 ARV Interruption Improves NP Performance Does CPE have a downside? A5170 found stopping ARV resulted in cognitive improvement ACTG 736 results suggested poorer performance in better penetrating regimens Elevated penetration could cause increased toxicity A=Control, B=ATV, C=EFV (dendrites), D=EFV(neuron loss) A C MAP 2 B D CROI 2010, Liner et al, Poster
31 Aging/HAART/HAND Does HIV or its therapy accelerate aging? Path evidence of premature p tau and amyloid Driving force could be chronic inflammatory or toxic Findings were subclinical but evident at post mortem Anthony et al, Acta Neuropathol, 2006 NNTC evaluation in HIV subjects yo Neuritic α synuclein in 12/73 HIV+ and not controls β amyloid deposits in 35/36 HIV brains Not found in association with HIV brain pathology Suggest accelerated degenerative disease not directly HIV virus driven 31
32 Chronic inflammatory state may lead to amyloid deposition TAT inhibition of neprilysn Ubiquitinproteosome dysfunction Potential Mechanisms Neurology, Dec
33 CSF Amyloid β 1 42 Is Low in Cognitively Impaired HIV+ Patients CSF Tau Not Elevated 33
34 Better Biomarkers: CSF Amyloid and PET PIB Biology of low CSFAB42 appears different in HIV and AD PIB binding correlates to low CSF AB42 in AD In HIV, low CSF AB42 is NOT associated itdwith extracellular amyloid deposits Ances and Clifford, Archives of Neurology, 2012 A. HIV +, Low Aβ1 42, cog N B. Community, Low Aβ 1 42, cog N Alzheimer s Disease in HIV AD is common and will likely occur in HIV patients as they age Rx for AD advancing, and specific dx will be important Anticholinesterase rx NMDA antagonist (memantine) HAND may be distinguished by: Lack of tau elevations in CSF Lack of PIB binding amyloid on PET scanning of brain More data needed on biology of amyloid in HIV (as well as AD!) 34
35 Slide 69 To develop effective treatment we need to know causes HAND now? Co-morbidities Virus Inflammation Drugs Perfusion/Vascular CROI 2010 Cardiovascular Risks Associated with Poor Cognitive Performance in SMART Study Traditional HIV associatedrisk factors were not associated with baseline NP performance CVD risk factors were associated with poorer baseline performance 35
36 Multicenter AIDS Cohort After accounting for education, depression and race Carotid intima media thickness (IMT) and GFR associated with psychomotor speed IMT associated with memory HIV serostatus not associated with poorer cognitive performance overall In HIV+, HIV detection in plasma associated with poorer memory HIV Indirectly Contributes to Cognitive Impairment? HIV Carotid Intima Thickening Age HBP DM Lipids Slide 72 Cognitive Normal Cognitive Impaired 36
37 Slide 73 Effects of HIV and Aging on rcbf Cere m/min) ebral blood flow (ml/100gm Age (years old) Ances et al., JID, Feb 2010 Slide 74 Blood Flow May be Biomarker for HIV Synaptodendritic Injury/Inflammation HIV Normal Synaptodendritic Density Normal Cerebral Blood Flow Masliah et al, Ann Neurol 1997 Masliah et al, Ann Neurol 1997 Disruption or Loss of Synaptodendritic communic ation Reduced d Cerebral Blood Flow HAART 37
38 Modifiable Risk Factors Slide 75 Smoking Diet Glucose Lipids Exercise Physical Mental Rest Modifiable Risk Factors Slide 76 Smoking Diet Glucose Lipids Exercise Physical Mental Rest 38
39 Overall NC Impairment status at baseline and last visit: No major cohort worsening Baseline Last Visit NP Normal Mild NCI NP Normal Mild NCI Moderate NCI Moderate NCI 8% 11% 38% 54% 29% 60% 77 Slide 78 Conclusions Cognitive functions remain impaired in many optimally treated HIV patients Optimal therapy should avoid low nadir CD4, optimize HIV control, minimize chronic immune activation, and optimize cerebral perfusion Healthy lifestyles as well as HIV control should contribute to better neurologic outcomes 39
40 Washington U Beau Ances Turner Overton ACTU and NARC staff NARC investigators Ned Sacktor Justin McArthur David Simpson Christina Marra Giovanni Schifitto Scott Evans CHARTER investigators Ron Ellis Scott Letendre Igor Grant NIH: NINDS (NARC and CHARTER) NIH: NIMH (CHARTER and CIT2) NIH: NIAID (ACTU) NIH: Fogarty (West Africa) Thanks 40
HIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationHIV Associated Neurocognitive Disorders in the era of modern CART
HIV Associated Neurocognitive Disorders in the era of modern CART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Points to be covered HIV associated
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV & Women: Neurological Issues
HIV & Women: Neurological Issues Scott Letendre, M.D. Professor of Medicine University of California, San Diego 1 Do women differ from men in their risk for neurocognitive and mood disorders? 2 As the
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationInternational Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 4rd Symposium on Psychiatry and HIV --- Barcelona, May 6th 2010 Neurocognitive Testing in HIV Infection: How to Implement this Assessment
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationIssues of Neuropsychological Assessment in International Settings
Issues of Neuropsychological Assessment in International Settings Kevin Robertson, Ph.D. Director of Neuropsychology, Neurology University of North Carolina at Chapel Hill Igor Grant, M.D. Director, HIV
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationDiagnosis and Monitoring of HAND
Diagnosis and Monitoring of HAND Norman C. Moore, MD Professor, Director of Research Department of Psychiatry and Behavioral Sciences Quillen College of Medicine APA 2015 Disclosure: Karl Goodkin, MD,
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationInternational Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationDidactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012
Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationHIV/AIDS HIV/AIDS: Outline. Morbidity and Mortality Weekly Report (MMWR)
HIV/AIDS: Outline HIV/AIDS 2013 Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell University New York City January 31, 2013 Epidemiology
More informationDefinitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders
Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders Prepared by Igor Grant for Working Group 1 consisting of: Desiree Byrd, Mariana Cherner, David
More informationApproach to HIV Associated Neurocognitive disorders (HAND)
Approach to HIV Associated Neurocognitive disorders (HAND) Dinesh Singh MB ChB (Natal), M Med (Psych) (Natal), F CPsych (SA), MS (epi) (Columbia, USA), PhD (candidate UKZN) 2 October 2009 ICC, Durban Overview
More informationMeasurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History
Measurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History Group Means for NP and MMPI Variables N=381 Consecutive
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationHIV Neurology Persistence of Cognitive Impairment Despite cart
HIV Neurology Persistence of Cognitive Impairment Despite cart Victor Valcour MD PhD Professor of Medicine Memory and Aging Center, Dept. of Neurology University of California San Francisco, USA 8 th International
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationHAND is Common and Important in Patients on ART
HAND is Common and Important in Patients on ART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego How is HAND diagnosed? How prevalent is it? Points
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationAIDS 2011, 3, 2011 RW
Treating CNS HIV Infection and Disease Why, How and When? Richard W. Price, M.D. Department of Neurology, UCSF/SFGH Preface: Reasons for Renewed Interest in Treatment of CNS HIV Continued CNS infection/disease
More informationClinical notes: Management of HAART in patients with HAND
Clinical notes: Management of HAART in patients with HAND Paola Cinque Dipartment of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy 11 Residential Course on Clinical Pharmacology
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationDSM-5 and HAND. Diagnosis and Monitoring of HAND 10/6/2015. APA Institute on Psychiatric Services New York City
Diagnosis and Monitoring of HAND Karl Goodkin, MD, PhD Professor and Chair Department of Psychiatry and Behavioral Sciences East Tennessee State University Norman C. Moore, MD Director of Research, Professor
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationThe Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationNEUROCOGNITIVE IMPAIRMENT IN A NEWLY DIAGNOSED HIV POSITIVE PATIENT WITH ADVANCED DISEASE
Vol XIV, Number 3, September 2010 Pages 224-230 Copyright reserved 2010 THERAPEUTICAL PRACTICE NEUROCOGNITIVE IMPAIRMENT IN A NEWLY DIAGNOSED HIV POSITIVE PATIENT WITH ADVANCED DISEASE Adriana Hristea
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationCAB 59: HIV and neurocogni5ve impairment
HIV Neurology CAB 59: HIV and neurocogni5ve impairment Friday 8 th July 2016 Dr Nick Davies Consultant Neurologist, Chelsea & Westminster Hospital & Imperial College NHS Trust (Charing Cross Hospital),
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationORIGINAL CONTRIBUTION. Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System
ORIGINAL CONTRIBUTION Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System Scott Letendre, MD; Jennifer Marquie-Beck, BS; Edmund
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationCNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz
CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz Question for the audience Do you think that any integrase inhibitor drug produce CNS adverse
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationHIV Update: What the Hospital-Based Provider Should Know
HIV Update: What the Hospital-Based Provider Should Know Steven C. Johnson M.D. Division of Infectious Diseases, University of Colorado School of Medicine October 6, 2011 45 year old female Case Study
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationHIV infection and Primary Care. HIV Care in /30/2013. It s not the AIDS of 85. Stephen Raffanti MD MPH Vanderbilt University School of Medicine
HIV infection and Primary Care Stephen Raffanti MD MPH Vanderbilt University School of Medicine HIV Care in 2013 Chronic lifelong treatment with all the associated issues: medication tolerability medication
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
More informationGaps between Policy and Practice in Managing HIV disease in Asia Pacific
Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Dr. N. Kumarasamy Chief Medical Officer YRGCARE Medical Centre Voluntary Health Services Chief-Chennai Antiviral Research and Treatment
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationVitamin D Deficiency in HIV: A Shadow on Long-Term Management?
AIDS Rev. 2014;16:59-74 (Supplementary Data) Vitamin D Deficiency in HIV: A Shadow on Long-Term Management? Chloe Orkin, et al.: Vitamin D deficiency in HIV (Supplementary Data) Chloe Orkin 1, David A.
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationThe Global HIV Epidemic. Jerome Larkin, MD
The Global HIV Epidemic Jerome Larkin, MD Outline Global Epidemiology Natural History of HIV Antiretroviral Therapy Malaria Tuberculosis Prevention of Mother to Child Transmission Post-Exposure Prophylaxis
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More information